Tag Archives: Patent

BMS deal quest gets a boost as Celgene swats aside another Revlimid patent challenge

Much of the investor doubt surrounding Bristol-Myers Squibb’s $ 74 billion Celgene buyout centers on the multiple myeloma blockbuster Revlimid—namely, whether its remaining patents can stand up to legal challenges. But the companies just scored a win in that department. Thursday, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) decided not… Read More »

U.S. top court rejects Amgen over cholesterol medication patent fight

WASHINGTON (Reuters) – Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial. FILE PHOTO: An Amgen sign is seen at… Read More »

Locked in a Sensipar patent fight, Teva rolled its generic anyway—and then Amgen settled

Amgen has been sweating potential copycats to its blockbuster calcium reducer Sensipar. But thanks to a patent deal with Teva, yet another challenger will have to wait until 2021 to sell its generic knockoff. This deal features a unique wrinkle, though. Teva had already launched its version, according to Bernstein analyst Ronny Gal, costing Amgen tens… Read More »